CHENGDU, China, Oct. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)...
Hence then, the article about third indication for kelun biotech s trop2 adc sac tmt approved for marketing by nmpa in egfrm nsclc following progression on egfr tki therapy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy )
Also on site :
- Johnny Knoxville Takes Credit For “Monstrous Explosion” In Simi Valley During ‘Jackass: Best and Last’ Wrap
- Indigo Girls’ Emily Saliers Reveals Cervical Dystonia and Essential Tremor Diagnoses: ‘My Voice Will Not Be What It Was’
- SK hynix Begins Mass Production of 192GB SOCAMM2 'Setting a New Standard for AI Server Memory Performance'